Drug Shortage Report for BEYFORTUS
| Report ID | 248064 |
| Drug Identification Number | 02537206 |
| Brand name | BEYFORTUS |
| Common or Proper name | NIRSEVIMAB |
| Company Name | SANOFI PASTEUR LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | NIRSEVIMAB |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 50 mg single-use, pre-filled syringe |
| ATC code | J06BD |
| ATC description | |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2025-01-20 |
| Actual start date | |
| Estimated end date | 2025-03-30 |
| Actual end date | 2025-02-12 |
| Shortage status | Resolved |
| Updated date | 2025-03-14 |
| Company comments | Sanofi is proactively securing additional doses from our global supply to quickly respond to an increase in demand, following inquiries for more doses to address a predicted surge in provincial uptake as the RSV season is projected to peak in January. The additional volumes are pre-emptive in nature and beyond the provincial contractual commitments. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1755 STEELES AVENUE WEST TORONTO, ONTARIO CANADA M2R 3T4 |
| Company contact information | Customer Service/Service à la clientèle: 1-800-268-4171 Vaccine Information Service/Service d'information sur les vaccins: 416-667-2611 or 1-888-621-1146 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2025-03-14 | French | Compare |
| v4 | 2025-03-14 | English | Compare |
| v3 | 2025-01-21 | English | Compare |
| v2 | 2025-01-17 | French | Compare |
| v1 | 2025-01-17 | English | Compare |
Showing 1 to 5 of 5